Drug Profile
Research programme: IAP inhibitors - AstraZeneca
Alternative Names: AZ-7732Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Amino acids
- Mechanism of Action Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA (IV)
- 21 Oct 2013 Early research in Cancer in USA (IV)